Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)

Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mutation T315I. Here we investigated the therapeutic poten...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Hematol
Autors principals: Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia, Ottmann, Oliver Gerhard, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin, Mahajna, Jamal
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8285356/
https://ncbi.nlm.nih.gov/pubmed/34110462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-020-04357-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars